EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide

Cheongin Yang, Changgon Kim, Kunye Kwak, Ka-Won Kang, Yong Park, Byung Soo Kim, Seong Hyun Jeong, Joon Seong Park, Yoon Seok Choi

Cancer Research and Treatment · 2026

DOI: 10.4143/crt.2025.418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Cheongin Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeThis retrospective study evaluated the efficacy and safety of a weekly carfilzomib, cyclophosphamide, and dexamethasone (KCd) regimen in patients with relapsed or refractory multiple myeloma (RRMM) who had been previously treated with both bortezomib- and lenalidomide-containing regimens.Materials and MethodsWe conducted a retrospective analysis of 33 patients with RRMM who received the KCd regimen between March 2020 and February 2024. All patients had prior exposure to both bortezomib and lenalidomide, and the majority (93.9%) were refractory to lenalidomide. Carfilzomib was administered once weekly at 70 mg/m2 (after a step-up dose), along with oral cyclophosphamide and dexamethasone. Treatment response was assessed according to the International Myeloma Working Group criteria, and survival outcomes were analyzed.Results The overall response rate was 66.7%, including a complete response or better in 15.1% of patients and a very good partial response or better in 42.4%. With a median follow-up of 31.7 months, the median progression-free survival was 13.5 months (95% confidence interval, 11.47 to 15.53), while the median overall survival was not reached. The most common grade ≥ 3 adverse event was neutropenia (15.2%). Non-hematologic grade ≥ 3 toxicities were infrequent and manageable.ConclusionThe weekly KCd regimen demonstrated encouraging efficacy and tolerability in a heavily pretreated RRMM population. These findings support its use as a feasible treatment option, particularly in patients refractory to lenalidomide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansDexamethasoneFemaleCyclophosphamideMaleLenalidomideMiddle AgedAgedRetrospective StudiesBortezomibOligopeptidesAdultDrug Resistance, NeoplasmAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

CarfilzomibCyclophosphamideMultiple myelomaRelapsed/refractorySafety profileTreatment outcome

Substanzen

DexamethasonecarfilzomibCyclophosphamideLenalidomideBortezomibOligopeptides

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT

Zitieren

APA

Yang, C., Kim, C., Kwak, K., Kang, K. W., Park, Y., Kim, B. S., Jeong, S. H., Park, J. S., & Choi, Y. S. (2026). Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.418

Vancouver

Yang C, Kim C, Kwak K, Kang KW, Park Y, Kim BS, et al. Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.418

BibTeX
@article{Yang2026,
  author = {Yang, Cheongin and Kim, Changgon and Kwak, Kunye and Kang, Ka-Won and Park, Yong and Kim, Byung Soo and Jeong, Seong Hyun and Park, Joon Seong and Choi, Yoon Seok},
  title = {Real-World Experience of Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Multiple Myeloma Relapsed/Refractory to Bortezomib and Lenalidomide},
  journal = {Cancer Research and Treatment},
  year = {2026},
  doi = {10.4143/crt.2025.418}
}
Kostenlos starten →